We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LILA:NASDAQLiberty Latin America Ltd. Analysis

Data as of 2026-08-23 - not real-time

$8.47

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Liberty Latin America Ltd. trades at $8.47, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. The last 30 days have gained 16.2%. With RSI at 59.4 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $7.59 and resistance at $8.90.
On valuation the read is undervalued — earnings multiple of 13.0 versus a 16.1 sector average, below the peer group. The average analyst target implies 30.7% above today's level.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 39.2%, a beta of 0.20 and a maximum drawdown of 22.9%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
This one splits by horizon — buy in the near term, hold further out, at 3/10 long-term conviction.

Top Market Events

Liberty Latin America reports 3% rebased OIBDA growth and unveils a $250 million AI-driven IT transformation deal with...DENVER, Colorado, July 27, 2026--Liberty Latin America Ltd.The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 5.92
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 13.0 versus sector average of 16.1
  • Trading above the 200-day average of 5.92

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 13.0 versus sector average of 16.1
  • Negative profit margin of -2.2%
  • Analyst targets imply +30.7% versus the current price

Key Metrics & Analysis

Financial Health

Revenue Growth1.50%
Profit Margin-2.20%
P/E Ratio13.0
ROE-3.72%
ROA1.28%
Debt/Equity905.53
P/B Ratio3.2
Op. Cash Flow$899.1M
Free Cash Flow$431.2M
Industry P/E16.1

Technical Analysis

TrendBullish
RSI59.4
Support$7.59
Resistance$8.90
MA 20$8.40
MA 50$7.48
MA 200$5.92
MACDBearish
VolumeDecreasing
Fear & Greed Index94.41

Valuation

Target Price$11.07
Upside/Downside30.66%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.20
Volatility39.23%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.